Actin Cross-Linking Effector Domain of the <i>Vibrio vulnificus</i> F-Type MARTX Toxin Dominates Disease Progression During Intestinal Infection-Reference-Cited by-同舟云学术

Actin Cross-Linking Effector Domain of the Vibrio vulnificus F-Type MARTX Toxin Dominates Disease Progression During Intestinal Infection

Published:2022-04-21 Issue:4 Volume:90 Page:
ISSN:0019-9567
Container-title:Infection and Immunity
language:en
Short-container-title:Infect Immun

Author:

Woida Patrick J.¹^ORCID,Kitts Giordan²,Shee Stephanie¹^ORCID,Godzik Adam³,Satchell Karla J. F.¹^ORCID

Affiliation:

1. Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA

2. Department of Microbiology and Environmental Toxicology, University of California at Santa Cruz, Santa Cruz, California, USA

3. Riverside School of Medicine, University of California, Riverside, California, USA

Abstract

Vibrio vulnificus is an opportunistic pathogen that causes gastroenteritis and septicemia in humans. The V. vulnificus multifunctional-autoprocessing repeats-in-toxin (MARTX) toxin is a pore-forming toxin that translocates multiple functionally independent effector domains into target cells and an essential virulence factor for fatal disease.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Link

https://journals.asm.org/doi/pdf/10.1128/iai.00627-21

Reference53 articles.

1. Vibrio vulnificus: new insights into a deadly opportunistic pathogen

2. The Biology of Vibrio vulnificus

3. Vibrio vulnificus

4. Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food: 10 states, 2006;Centers for Disease Control and Prevention (CDC);MMWR Morb Mortal Wkly Rep,2007

5. Vibrio vulnificus: An Environmental and Clinical Burden

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Divergence of Vibrio vulnificus Clinical Isolates with Mild to Severe Outcomes;mBio;2022-10-26